Sucampo Pharma Americas

Sucampo Pharmaceuticals was a biopharmaceutical company focused on the development and commercialization of specialized medicines, particularly in the fields of gastroenterology, ophthalmology, and rare diseases. The company's flagship product, Amitiza (lubiprostone), is a chloride channel activator approved for various forms of constipation and irritable bowel syndrome. In early 2018, Sucampo was acquired by Mallinckrodt Pharmaceuticals for approximately $1.2 billion, integrating its commercial portfolio and late-stage pipeline into Mallinckrodt's specialty brands. At the time of acquisition, Sucampo was advancing treatments for Niemann-Pick Disease Type C and Familial Adenomatous Polyposis.